Posted on

livingwithpain org cbd

Livingwithpain org cbd

Previous president of IASP Dr. Lars Arendt-Nielsen, who established and co-chaired the Task Force emphasize that “IASP is also calling for the delivery of a comprehensive research agenda. Priorities include identifying patients with pain who may receive the most benefit from cannabis or cannabinoids, and who may be at risk of the most harm. It is also necessary to expand the range of chemical entities tested, identify appropriate doses and their effects, and determine optimal delivery methods.”

In addition to the statement, the IASP journal PAIN has published a series of 13 linked scientific articles that comprehensively review all of the relevant laboratory and clinical research on this topic. These reviews took place over the last two-and-a-half years and represent the work of IASP’s Presidential Task Force on Cannabis and Cannabinoid Analgesia. These articles form the body of evidence that informed IASP’s position.

With more than 5,800 members representing 134 countries, 96 national chapters, and 24 Special Interest Groups (SIGs), IASP fosters the exchange of ideas and education to advance the field of pain science. Membership is open to all professionals involved in research, diagnosis, or treatment of pain. Patients with lived experiences contribute at all levels in the organization.

Contact:

WASHINGTON, DC – MARCH 18, 2021 – The International Association for the Study of Pain (IASP) said in a statement today that due to a lack of evidence from high quality research, it does not endorse the general use of cannabinoids [1] to treat pain. IASP has also published a list of research priorities which need to be addressed in order to properly determine the potential efficacy, and to confirm the safety of, cannabinoids when used in the treatment of pain.

Although there are preclinical data supporting the hypothesis of cannabinoid analgesia, current uncertainties, especially in the clinical evidence, dictate that the evidence base regarding efficacy and safety fails to reach the threshold at which IASP can endorse their general use for pain control. The studies and the statement are limited to the use of cannabinoids to treat pain, and not for other conditions for which cannabinoids are currently being used.

About IASP

Livingwithpain org cbd

by Garrett Schaffel, AARP, June 7, 2018

The compound from marijuana plants shows promise for age-related health problems

While there is growing interest among scientists to study CBD’s causes and effects, researchers are hindered by marijuana’s Drug Enforcement Agency Schedule I classification, meaning it is considered in the same drug class as heroin.

En español | Nancy Giacobbe has been a medical marijuana cardholder since the legalization of medicinal use of the plant in California in 2008. But in 2014, her husband Chris had trouble sleeping due to painful spasms and tremors caused by treatments for a rare form of cancer. While Giacobbe, 61, had used the plant for its psychoactive properties (i.e., the high produced by tetrahydrocannabinol, or THC) she soon saw the medicinal benefits of the plant’s other, lesser-known compound — cannabidiol, or CBD — when Chris began to use it for his pain.